A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore Challenge

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Manish, Manish ^a   Rahi, Amit ^a   Kaur, Manpreet ^a   Bhatnagar, Rakesh ^a   Singh, Samer ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; NANOPARTICLE; POLYGLACTIN; PROTECTIVE ANTIGEN DOMAIN 4; RECOMBINANT PROTECTIVE ANTIGEN DOMAIN 4; UNCLASSIFIED DRUG; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; CYTOKINE; DRUG CARRIER; IMMUNOGLOBULIN G; LACTIC ACID; MICROCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTHRAX; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DISPERSION; DRUG EFFICACY; DRUG FORMULATION; EVAPORATION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; MORPHOLOGY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SINGLE DRUG DOSE; SURVIVAL RATE; TH1 CELL; TH2 CELL; ZETA POTENTIAL; ANIMAL; ANTIBODY SPECIFICITY; BACTERIAL SPORE; CHEMISTRY; IMMUNOLOGY; MEDICINAL CHEMISTRY; METABOLISM; MICROCAPSULE; PHYSIOLOGY; SURVIVAL;

BACILLUS ANTHRACIS; MUS;

ANIMALS; ANTHRAX VACCINES; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG CARRIERS; FEMALE; IMMUNOGLOBULIN G; LACTIC ACID; MICE; NANOPARTICLES; POLYGLYCOLIC ACID; SPORES, BACTERIAL; SURVIVAL ANALYSIS; TH1 CELLS; TH2 CELLS;

EID: 84876944573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061885     Document Type: Article

References (50)

1. Mourez M, (2004) Anthrax toxins. Rev Physiol Biochem Pharmacol 152: 135-164.
2. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, et al. (1993) Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167: 1239-1243.
3. Borio L, Frank D, Mani V, Chiriboga C, Pollanen M, et al. (2001) Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA 286: 2554-2559.
4. Leppla SH, Robbins JB, Schneerson R, Shiloach J, (2002) Development of an improved vaccine for anthrax. J Clin Invest 110: 141-144.
5. Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, et al. (2007) Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75: 4020-4029.
6. Kaur M, Bhatnagar R, (2011) Recent progress in the development of anthrax vaccines. Recent Pat Biotechnol 5: 148-159.
7. Franz DR, (2009) Preparedness for an anthrax attack. Mol Aspects Med 30: 503-510.
8. Tournier J-N, Ulrich RG, Quesnel-Hellmann A, Mohamadzadeh M, Stiles BG, (2009) Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther 7: 219-236.
9. Friedlander AM, Little SF, (2009) Advances in the development of next-generation anthrax vaccines. Vaccine 27Suppl 4: D28-32.
10. Brey RN, (2005) Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57: 1266-1292.
11. Baillie LW, (2009) Is new always better than old?: The development of human vaccines for anthrax. Hum Vaccin 5: 806-816.
12. Zomber G, Reuveny S, Garti N, Shafferman A, Elhanany E, (2005) Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen. J Biol Chem 280: 39897-39906.
13. Jiang GE, Joshi SB, Peek LJ, Brandau DT, Huang J, et al. (2006) Anthrax Vaccine Powder Formulations for Nasal Mucosal Delivery. J Pharm Sci 95: 80-96 doi:10.1002/jps.20484.
14. Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, et al. (2012) Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. J Pharm Sci 101: 4118-4128.
15. McBride BW, Mogg a, Telfer JL, Lever MS, Miller J, et al. (1998) Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16: 810-817.
16. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, et al. (2012) Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin Vaccine Immunol 19: 1465-1473.
17. Akagi T, Baba M, Akashi M, (2012) Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine. In: Shigeru K, Yamaoka T, editors. Polymers in Nanomedicine. Springer Berlin Heidelberg, Vol. 247: 31-64.
18. Anderson JM, Shive MS, (2012) Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 64: 72-82.
19. Makadia HK, Siegel SJ, (2011) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers 3: 1377-1397 doi:10.3390/polym3031377.
20. Lee Y-R, Lee Y-H, Im S-A, Kim K, Lee C-K, (2011) Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen. Immune Netw 11: 163-168.
21. Flick-smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, et al. (2002) Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice. Infect Immun 70: 2022-2028 doi:10.1128/IAI.70.4.2022.
22. Williams AS, Lovell S, Anbanandam A, El-Chami R, Bann JG, (2009) Domain 4 of the anthrax protective antigen maintains structure and binding to the host receptor CMG2 at low pH. Protein Sci 18: 2277-2286.
23. Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, et al. (2002) A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 70: 1653-1656.
24. Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, et al. (2011) A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax. Vaccine 29: 4521-4533.
25. Brodzik R, Bandurska K, Deka D, Golovkin M, Koprowski H, (2005) Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta. Biochem Biophys Res Commun 338: 717-722.
26. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, et al. (2006) Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 353: 344-356.
27. Langley WA, Bradley KC, Li Z-N, Smith ME, Schnell MJ, et al. (2010) Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol 84: 8300-8307.
28. Ganesan A, Watkinson A, Moore BD, (2012) Biophysical characterisation of thermal-induced precipitates of recombinant anthrax protective antigen: Evidence for kinetically trapped unfolding domains in solid-state. Eur J Pharm Biopharm 82: 475-484.
29. Frey A, Di J, Zurakowski D, (1998) A statistically defined endpoint titer determination method for immunoassays: J Immunol Methods. 221: 35-41.
30. Li X, Sloat BR, Yanasarn N, Cui Z, (2011) Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm 78: 107-116.
31. Oyewumi MO, Kumar A, Cui Z, (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9: 1095-1107.
32. Flick-Smith HC, Waters EL, Walker NJ, Miller J, Stagg AJ, et al. (2005) Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb Pathog 38: 33-40.
33. Quinn CP, Sabourin CL, Niemuth NA, Li H, Semenova VA, et al. (2012) A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus Macaques. Clin Vaccine Immunol 19: 1730-1745.
34. Kaur M, Chug H, Singh H, Chandra S, Mishra M, et al. (2009) Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol Immunol 46: 2107-2115.
35. Welkos SL, Keener TJ, Gibbs PH, (1986) Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 51: 795-800.
36. Leggett HC, Cornwallis CK, West SA, (2012) Mechanisms of pathogenesis, infective dose and virulence in human parasites. PLoS Pathog 8: e1002512.
37. Plaut RD, Kelly VK, Lee GM, Stibitz S, Merkel TJ, (2012) Dissemination bottleneck in a murine model of inhalational anthrax. Infect Immun 80: 3189-3193.
38. Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, et al. (2012) Comparison of the Structural Stability and Dynamic Properties of Recombinant Anthrax Protective Antigen and Its 2-Fluorohistidine-Labeled Analogue. J Pharm Sci101: 4118-4128.
39. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT, (2007) PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm 331: 228-232.
40. Radha C, Salotra P, Bhat R, Bhatnagar R, (1996) Thermostabilization of protective antigen-the binding component of anthrax lethal toxin. J Biotechnol 50: 235-242.
41. Singh S, Ahuja N, Chauhan V, Rajasekaran E, Mohsin Waheed S, et al. (2002) Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis. Biochem Biophys Res Commun 296: 1058-1062.
42. Kumari A, Yadav SK, Yadav SC, (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75: 1-18.
43. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, et al. (2012) Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 33: 4957-4964.
44. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, et al. (2012) Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 7: e31472.
45. Santos DM, Carneiro MW, De Moura TR, Fukutani K, Clarencio J, et al. (2012) Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. Int J Nanomedicine 7: 2115-2127.
46. Lutsiak MEC, Kwon GS, Samuel J, (2006) Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 58: 739-747.
47. Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47 doi:10.1038/nri2206.
48. Abboud N, Chow S-K, Saylor C, Janda A, Ravetch JV, et al. (2010) A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med 207: 2395-2405.
49. Merkel TJ, Perera P-Y, Kelly VK, Verma A, Llewellyn ZN, et al. (2010) Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci U S A 107: 18091-18096.
50. Cote CK, Rossi CA, Kang AS, Morrow PR, Lee JS, et al. (2005) The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb Pathog 38: 209-225.